Interesting INDV Put And Call Options For March 20th

Stock Options Channel highlights two INDV option strategies: selling the $28 put (bid $0.80) which nets a $27.20 effective share cost versus the $32.32 market price (≈13% OTM) with a 74% chance to expire worthless, yielding 2.86% (16.56% annualized) if it does. The covered-call trade involves selling the $36 call (bid $1.20) against shares bought at $32.32, offering a 15.10% total return if called at the March 20 expiration (≈11% OTM) with a 61% chance to expire worthless and a 3.71% YieldBoost (21.53% annualized); implied vols are 88% (put) and 53% (call) versus a 12‑month realized volatility of 50%.

Analysis

Market structure: The immediacy of a liquid $28 put (bid $0.80) and a $36 call ($1.20) benefits option premium collectors, market makers, and cash-secured yield-seeking investors; downside is concentrated on sellers of naked puts and holders forced to buy at $28. High put IV (88%) vs realized vol (50%) and asymmetric skew signals market-implied left-tail risk specific to INDV rather than broad market stress. Cross-asset impact is limited, but option flows could widen INDV’s bid/ask, increase stock financing costs and modestly raise correlations with biotech vol indices over the next 30–90 days.

Risk assessment: Tail risks are regulatory/legal surprises (e.g., FDA rulings, opioid litigation) or an earnings/clinical miss that could gap downside >30% within days — implied by the put skew. Immediate horizon (days–weeks): theta decay favors sellers but IV spikes can blow up P/L; short-term (weeks–months): assignments around Mar 20 expiry (~63 days away) are primary event risk; long-term (quarters+): fundamental revenue/label risk will drive realized vol toward or away from current 50% baseline. Hidden dependency: high put IV reflects concentrated short interest or block hedging; a single adverse press release could cascade via forced deleveraging.

Trade implications: For neutral-to-mildly-bullish exposure use cash-secured put: sell INDV Mar20 $28 put for $0.80 (net basis $27.20) but size <=2% portfolio and set hard stop if INDV < $26 or IV jumps +25% intraday. For income with capped upside buy INDV at ~$32.32 and sell Mar20 $36 call, collecting $1.20 (15.1% to strike); trim if shares move >+11% pre-expiry. If worried about left tail, buy protection (Mar20 $24 put) to cap loss below $24; prefer buying protection when put IV compresses <70%.

Contrarian view: Consensus treats 74% chance the $28 put expires worthless but underestimates asymmetric regulatory/legal downside that justifies the elevated 88% put IV; selling naked puts without hedges is likely underpriced. Historical parallels (small-cap pharma with concentrated products) show volatility can re-rate [phone] bps quickly on single legal/FDA events; therefore prefer defined-risk option structures (debit spreads, collars) rather than naked short premium despite attractive annualized yields (16–22%).

Key Decisions for Investors

• Establish a cash-secured short put: sell INDV Mar20 $28 put at $0.80 (net basis $27.20) sized to 1–2% of portfolio; exit or hedge if INDV < $26 or option IV increases >25% intraday.
• Buy-and-cover (covered call): buy INDV at ~32.32 and sell Mar20 $36 call for $1.20 to target 15.1% upside to strike; cap allocation at 2–3% and close the call if stock >$36 or IV falls >20% before expiry.
• Buy downside protection if long INDV: purchase Mar20 $24 put as a hedge to limit loss below $24 (target premium ≤$0.80); if $24 puts trade >$0.80, use 1x bought put + 1x sold $20 put (debit put spread) to define risk.
• Avoid naked put selling >3% portfolio exposure and prefer defined-risk spreads (debit/collar) until post-March catalysts (earnings/FDA/legal filings) clear; monitor short interest and 10‑day IV move >30% as stop/rehedge triggers.
• Monitor specific catalysts over next 30–90 days: INDV filings/press releases, FDA or court rulings, quarterly results and block trades; any one of these moving adverse news should prompt converting short premium positions into collars within 48 hours.